Valius Sciences Raises $13.5 Million Seed Round to Advance AI-Powered Cancer Diagnostics
Valius Sciences has raised $13.5 million in seed funding to accelerate the development of its AI-driven cancer diagnostics platform, a milestone that positions the biotechnology company to expand its capabilities in precision oncology. The financing round was co-led by 8VC and Basis Set Ventures, with participation from Compound, Define Ventures, and Even One Ventures.
Founded in 2025 and headquartered in San Francisco, Valius Sciences is building a comprehensive molecular diagnostics platform designed to help oncologists make more informed treatment decisions for cancer patients. The company combines advanced laboratory testing with artificial intelligence and computational biology to analyze tumors at multiple biological levels, including DNA, RNA, proteins, and other molecular signals. By integrating these datasets, Valius aims to uncover therapeutic opportunities that may not be identified through conventional diagnostic testing.
The newly secured capital will support the expansion of the company’s scientific, engineering, and bioinformatics teams while accelerating research and development across its platform. Valius plans to invest in additional diagnostic capabilities, including single-cell gene expression analysis, which enables researchers to study individual cells within a tumor rather than examining the tumor as a whole. The company believes this approach can provide deeper insights into cancer biology and improve the identification of targeted treatment options for patients.
Valius Sciences describes its approach as “maximalist” cancer diagnostics, arguing that many current testing methods evaluate only a limited portion of the biological information available within a patient’s tumor. By generating a more comprehensive molecular profile, the company seeks to provide physicians with richer data that can help guide treatment selection, including approved therapies, off-label medications, clinical trials, and investigational approaches where appropriate.
Unlike many diagnostic providers that focus solely on delivering laboratory reports, Valius emphasizes collaboration with oncologists and patients throughout the treatment journey. The company works alongside clinical teams to interpret complex molecular findings and translate them into actionable insights. Its platform is designed not only to identify potential therapeutic targets but also to provide contextual analysis that helps clinicians understand the significance of the results.
The leadership team brings together expertise from biotechnology, healthcare technology, computational biology, and precision medicine. Founder and Chief Executive Officer Edward Larkin previously helped build the healthcare business at Palantir Technologies before working as an investor at Dragoneer Investment Group. The company’s advisors and scientific collaborators include experts with experience at leading research institutions and cancer centers, reflecting Valius’ focus on combining cutting-edge science with practical clinical applications.
Valius’ diagnostic workflow incorporates multiple advanced technologies, including whole-genome sequencing, RNA sequencing, protein profiling, spatial RNA analysis, and ultra-sensitive circulating tumor DNA testing. The resulting datasets are analyzed using computational methods that compare a patient’s tumor characteristics with large biological datasets to identify potential treatment opportunities. This integrated approach is intended to provide a more complete understanding of each patient’s disease than traditional single-test diagnostics.
The seed financing underscores continued investor interest in companies operating at the intersection of artificial intelligence, genomics, and precision medicine. As oncology increasingly shifts toward personalized treatment strategies, startups capable of integrating large-scale molecular data into clinically useful recommendations have attracted significant attention from venture capital firms. Investors see opportunities for technologies that can help physicians better match patients with therapies based on the unique biological characteristics of their cancers.
With the new funding, Valius Sciences plans to continue expanding its platform, strengthen its multidisciplinary team, and broaden access to its diagnostic services. The company aims to make comprehensive molecular profiling a more widely available tool for oncologists treating patients with complex or treatment-resistant cancers. By combining extensive laboratory analysis with AI-powered interpretation, Valius hopes to improve clinical decision-making and enable more personalized cancer care, supporting physicians in identifying therapeutic options that may otherwise remain undiscovered.
